$266.58
1.39% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$266.58
+32.95 14.10% 1M
+86.51 48.04% 6M
+49.60 22.86% YTD
+78.84 41.99% 1Y
-30.98 10.41% 3Y
+85.42 47.15% 5Y
+221.10 486.15% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+3.65 1.39%
ISIN
US45784P1012
Symbol
PODD
Sector

Key metrics

Market capitalization $18.70b
Enterprise Value $19.19b
P/E (TTM) P/E ratio 45.33
EV/FCF (TTM) EV/FCF 84.60
EV/Sales (TTM) EV/Sales 9.68
P/S ratio (TTM) P/S ratio 9.43
P/B ratio (TTM) P/B ratio 16.72
Revenue growth (TTM) Revenue growth 27.42%
Revenue (TTM) Revenue $1.98b
EBIT (operating result TTM) EBIT $306.00m
Free Cash Flow (TTM) Free Cash Flow $226.90m
Cash position $902.60m
EPS (TTM) EPS $5.88
P/E forward 78.94
P/S forward 9.10
EV/Sales forward 9.34
Short interest 5.41%
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Insulet Corporation forecast:

20x Buy
77%
5x Hold
19%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Insulet Corporation forecast:

Buy
77%
Hold
19%
Sell
4%

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,984 1,984
27% 27%
100%
- Direct Costs 595 595
9% 9%
30%
1,389 1,389
37% 37%
70%
- Selling and Administrative Expenses 799 799
35% 35%
40%
- Research and Development Expense 201 201
5% 5%
10%
389 389
88% 88%
20%
- Depreciation and Amortization 83 83
18% 18%
4%
EBIT (Operating Income) EBIT 306 306
123% 123%
15%
Net Profit 421 421
251% 251%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Positive
Seeking Alpha
6 days ago
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and ...
Neutral
Business Wire
6 days ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most conn...
Neutral
Business Wire
11 days ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq...
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO James Hollingshead
Employees 3,000
Founded 2000
Website www.insulet.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today